Successful Treatment of Gram-Negative Bacillary Meningitis With Imipenem/Cilastatin

Rodriguez, Kellie; Dickinson, Gordon M.; Greenman, Richard L.

doi:10.1097/00007611-198506000-00028

Cited by 10 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The final case report describes an 18-year old treated with Acinetobacter anitratus meningitis sensitive only to imipenem/cilastatin [13]. The patient received 1 g every 6 h for 14 days.…”

Section: Literature Reviewmentioning

confidence: 99%

Safety of Imipenem/Cilastatin in Neurocritical Care Patients

2008

View full text Add to dashboard Cite

show abstract

“…The final case report describes an 18-year old treated with Acinetobacter anitratus meningitis sensitive only to imipenem/cilastatin [13]. The patient received 1 g every 6 h for 14 days.…”

Section: Literature Reviewmentioning

confidence: 99%

Safety of Imipenem/Cilastatin in Neurocritical Care Patients

2008

View full text Add to dashboard Cite

show abstract

“…Twenty infants and children with meningitis caused by Citrobacter diversus were treated with imipenem/cilastatin intravenously at a daily dose of 80 mg/kg and the meningitis is cured in all patients [45]. Ten adult patients had the meningitis caused by Acinetobacter anitratus and were treated with imipenem/cilastatin intravenously at a dose of 1 gram 4 times-daily and the meningitis is cured after 12 days of therapy and the treatment is well-tolerated [46]. In conclusion, imipenem is a β-lactam antibiotic and is market in combination with cilastatin a drug that inhibits the degradation of imipenem by renal tubular dipeptidase and extends the elimination half-life of imipenem.…”

Section: Discussionmentioning

confidence: 99%

“…Ten adult patients had the meningitis caused by Acinetobacter anitratus and were treated with imipenem/cilastatin intravenously at a dose of 1 gram 4 times-daily. The minimal inhibitory concentration of imipenem against Acinetobacter anitratus is ≤ 0.04 μg/ml, the patients tolerate the drug well, and the meningitis is cured after 12 days of therapy [46].…”

Section: Treatment Of Bacterial Meningitis With Imipenem/cilastatinmentioning

confidence: 99%

Clinical Pharmacology of Imipenem/Cilastatin

Pacifici

2023

BJSTR

View full text Add to dashboard Cite

Imipenem is a β-lactam antibiotic and is market in combination with cilastatin a drug that inhibits the degradation of imipenem by renal tubular dipeptidase and extends the elimination half-life of imipenem. Imipenem binds to penicillin-binding proteins, disrupts bacterial cell wall synthesis, and causes depth of susceptible organisms. Imipenem is resistant to hydrolysis by most β-lactamases and is active against a wide variety of aerobic and anaerobic microorganisms. Streptococci (including penicillinase-resistant Streptococcus pneumoniae), Enterococcus faecalis, staphylococci (including penicillinase-producing strains but not methicillin-resistant Staphylococcus aureus), Listeria, Enterobacteriaceae (except for emerging carbapenemase-producing strains), most strains of Pseudomonas and Acinetobacter, and Bacillus fragilis are susceptible to imipenem/cilastatin. Imipenem/cilastatin effectively treats urinarytract, lower respiratory, intraabdominal, gynaecologic, skin, soft-tissue, bone, and joint infections. The efficacy and safely of imipenem/cilastatin and the penetration of imipenem in muscle and in subcutaneous tissues have been reviewed. The pharmacokinetics of imipenem have been studied in heathy volunteers and in patients with severe renal failure and the elimination half-life of imipenem is longer in patients than in healthy volunteers. The treatment of bacterial infections and trials with imipenem/cilastatin have been reviewed. Imipenem penetrates into the cerebrospinal fluid in significant amounts and imipenem/ cilastatin treats the meningitis caused by Haemophilus influenzae type b, Citrobacter diversus, or Acinetobacter anitratus. The aim of this study is to review imipenem/cilastatin efficacy and safely, treatment of bacterial infections, trials, and treatment of bacterial meningitis, imipenem diffusion in tissues, and pharmacokinetics of imipenem and cilastatin and penetration into the cerebrospinal fluid of imipenem and cilastatin.

show abstract

“…Imipenem has not been used extensively in the treatment of central nervous system infections in humans (33), primarily because seizures have been noted in some patients who had predisposing conditions and received high doses and or had renal insufficiency (4). In a therapeutic trial of meningitis in children, 7 children (33%) developed seizures while receiving therapy (46).…”

Section: Discussionmentioning

confidence: 99%

Therapy of experimental meningitis due to Salmonella enteritidis

Bryan

Scheld

1992

Antimicrob Agents Chemother

View full text Add to dashboard Cite

In many areas of the developing world, Salmonella spp. account for greater than 50% of the gram-negative enteric organisms isolated from cerebrospinal fluid (CSF). The response of Salmonella meningitis to conventional therapy (chloramphenicol and/or ampicillin) is slow, complications arise frequently, and mortality rates of 60 to 80% are common. Two newer agents, ceftriaxone and imipenem, were compared with ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole (TMP-SMX) in the therapy of experimental Salmonella meningitis beginning 14 h after intracisternal inoculation and continued by constant intravenous infusion for 8 h. Drug concentrations in serum and CSF closely approximated those achieved in the sera and CSF of humans receiving standard parenteral regimens. Penetration into purulent CSF [(concentration of drug in CSF/concentration of drug in serum) x 100] ranged from 18 to 41%. The rate of bacterial killing in CSF was significantly (P less than 0.001) more rapid during therapy with ceftriaxone and imipenem than it was during therapy with chloramphenicol or TMP-SMX. Ceftriaxone and imipenem sterilized the CSF of six of seven animals at 8 h, whereas it sterilized the CSF of three of eight animals treated with ampicillin (P = 0.18), one of eight animals treated with chloramphenicol, and none of seven animals treated with TMP-SMX (P less than or equal to 0.01; ceftriaxone or imipenem versus chloramphenicol or TMP-SMX). New beta-lactams, including ceftriaxone and imipenem, appear to be effective therapy against Salmonella spp. in this animal model and deserve further evaluation in humans.

show abstract

Successful Treatment of Gram-Negative Bacillary Meningitis With Imipenem/Cilastatin

Cited by 10 publications

References 0 publications

Safety of Imipenem/Cilastatin in Neurocritical Care Patients

Safety of Imipenem/Cilastatin in Neurocritical Care Patients

Clinical Pharmacology of Imipenem/Cilastatin

Therapy of experimental meningitis due to Salmonella enteritidis

Contact Info

Product

Resources

About